Cyclin E1 as a therapeutic target in women with high-grade serous cancer and primary treatment failure

卵巢癌是女性第五大常见癌症，也是最致命的妇科恶性肿瘤。我们发现具有CyclinE1基因（CCNE1）额外拷贝的肿瘤不太可能对标准治疗产生反应，并且表现出对其活性的依赖。因此，靶向CCNE1可能是这些癌症的一种新的治疗策略。我们将对CCNE1通路的治疗性抑制剂进行临床前研究，并进一步探索CCNE1扩增肿瘤的潜在生物学。

Ovarian cancer is the 5th most common cancer in women and the most lethal gynaecologic malignancy. We found tumours with extra copies of the CyclinE1 gene (CCNE1) are less likely to respond to standard treatment, and show reliance on its activity. Therefore, targeting CCNE1 may be a novel treatment strategy for these cancers. We will perform preclinical studies with therapeutic inhibitors towards the CCNE1 pathway and further explore the underlying biology of tumours with CCNE1 amplification.